Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma Inc (NYSE American: IGC) is a clinical-stage biotechnology leader pioneering AI-driven cannabinoid therapies for Alzheimer’s disease, chronic pain, and neurological disorders. This page provides investors and researchers with timely updates on the company’s pharmaceutical advancements, clinical trial progress, and strategic initiatives.
Access comprehensive coverage of IGC’s investigational drug pipeline, including IGC-AD1 for Alzheimer’s-related agitation currently in Phase 2 trials. Stay informed about cutting-edge research integrating artificial intelligence to optimize therapeutic development and diagnostic precision.
Explore updates across key areas: clinical trial milestones, regulatory developments, research partnerships, and product launches from the Holiby™ wellness brand. Our curated news collection ensures you never miss critical updates about IGC’s dual focus on pharmaceutical innovation and consumer health solutions.
Bookmark this page for verified information on IGC Pharma’s advancements in cannabinoid science, AI applications in drug discovery, and market-moving developments. Check regularly for authoritative reporting on one of biotech’s most innovative players.
IGC Pharma, Inc. (NYSE American:IGC) has announced its participation in the Planet MicroCap Showcase: VEGAS 2023, scheduled for April 26, 2023, at 4:30 PM PDT. CEO Ram Mukunda and CFO Claudia Grimaldi will present and engage in a Q&A session following the presentation.
Investors can access the live presentation via webcast here. Registration for 1x1 investor meetings at the event is available here. The showcase aims to enhance awareness about MicroCap investments.
IGC Pharma focuses on cannabinoid-based formulations for various medical conditions, including Alzheimer’s disease and PMS. The company is currently conducting a Phase 2 clinical trial for its drug IGC-AD1 targeting agitation in Alzheimer’s patients.
India Globalization Capital, Inc. (IGC) reported impressive third fiscal quarter 2023 results, with net revenue soaring 133% to $332,000 year-over-year, driven by its life science segment. The company is advancing its Phase 2 clinical trial for IGC-AD1, targeting agitation in dementia due to Alzheimer’s, expanding sites from four to up to 12 to enhance enrollment. The trial aims to involve 146 patients and establish efficacy over six weeks. R&D expenses rose to $806,000 due to increased trial activities, while SG&A expenses decreased to $1.5 million. Despite a net loss of $2.2 million, IGC remains optimistic about expanding its market presence and future FDA approval.
India Globalization Capital (NYSE American: IGC) announces an upcoming investor webinar featuring CEO Ram Mukunda and PFO Claudia Grimaldi on February 10, 2023, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for IGC-AD1, aimed at alleviating agitation in Alzheimer's patients. The trial involves 146 participants and is categorized as Phase 2B for safety and efficacy. IGC is focused on developing cannabinoid-based formulations for various conditions, including Alzheimer’s disease. The Company also markets wellness brands Holief and Sunday Seltzer.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
